Signals, Powered By EquityPandit
Alembic Pharma has got the USFDA’s final approval for Lacosamide tablets which are used for the treatment of partial-onset seizures in the American market.
Alembic Pharmaceuticals said in a BSE filing “The company has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg.”
It further added that the product is a generic version of drug firm UCB Inc’s Vimpant tablets in the same strengths.
